LMR Partners’s Iovance Biotherapeutics IOVA Stock Holding History

LMR Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$171K	Hold	41,211	–	–	﹤0.01%	1336
2026 Q1	$145K	Hold	41,211	–	–	﹤0.01%	1226
2025 Q4	$113K	Hold	41,211	–	–	﹤0.01%	1334
2025 Q3	$89.4K	Hold	41,211	–	–	﹤0.01%	1287
2025 Q2	$70.9K	Hold	41,211	–	–	﹤0.01%	1197
2025 Q1	$137K	Hold	41,211	–	–	﹤0.01%	1106
2024 Q4	$305K	Hold	41,211	–	–	﹤0.01%	901
2024 Q3	$387K	Sell	41,211 -20,000	-33%	-$189K	﹤0.01%	874
2024 Q2	$491K	Sell	61,211 -60,400	-50%	-$647K	﹤0.01%	773
2024 Q1	$1.8M	Buy	121,611 +80,400	+195%	+$936K	0.02%	568
2023 Q4	$335K	Hold	41,211	–	–	﹤0.01%	688
2023 Q3	$188K	Hold	41,211	–	–	﹤0.01%	644
2023 Q2	$290K	Hold	41,211	–	–	﹤0.01%	555
2023 Q1	$252K	Sell	41,211 -10,000	-20%	-$69K	﹤0.01%	830
2022 Q4	$327K	Hold	51,211	–	–	0.01%	944
2022 Q3	$491K	Hold	51,211	–	–	0.01%	888
2022 Q2	$565K	Hold	51,211	–	–	0.01%	887
2022 Q1	$853K	Sell	51,211 -10,000	-16%	-$155K	0.01%	869
2021 Q4	$1.17M	Hold	61,211	–	–	0.01%	655
2021 Q3	$1.51M	Buy	61,211 +39,265	+179%	+$925K	0.02%	523
2021 Q2	$571K	Buy	+21,946	New	+$570K	0.01%	645
2020 Q4	–	Sell	-49,504	Closed	-$1.63M	–	553
2020 Q3	$1.63M	Sell	49,504 -8,736	-15%	-$268K	0.03%	171
2020 Q2	$1.6M	Buy	+58,240	New	+$1.91M	0.04%	292

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

LMR Partners's IOVA Position: Q2 2026 in Review

LMR Partners held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 41,211 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

LMR Partners first reported a position in IOVA in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.8M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

LMR Partners held 41,211 shares of Iovance Biotherapeutics worth $171K as of Q2 2026.
LMR Partners left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1336 holding.
LMR Partners first reported a position in Iovance Biotherapeutics in Q2 2020 and has held it in 23 quarters since.
LMR Partners's Iovance Biotherapeutics position peaked at $1.8M in Q1 2024.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.